Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Genprex Inc (GNPX)
Genprex Inc (GNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,670
  • Shares Outstanding, K 59,435
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,740 K
  • 60-Month Beta -0.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.16
Trade GNPX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.62
  • Most Recent Earnings -0.13 on 11/14/23
  • Next Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 1,029.90% ( +442.30%)
  • Historical Volatility 137.37%
  • IV Percentile 97%
  • IV Rank 71.52%
  • IV High 1,416.48% on 06/16/23
  • IV Low 59.02% on 11/15/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 21
  • Volume Avg (30-Day) 133
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,928
  • Open Int (30-Day) 3,455

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +73.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2178 +6.06%
on 11/09/23
0.2800 -17.50%
on 11/27/23
-0.0140 (-5.71%)
since 11/08/23
3-Month
0.1903 +21.39%
on 10/27/23
0.5600 -58.75%
on 09/13/23
-0.3090 (-57.22%)
since 09/08/23
52-Week
0.1903 +21.39%
on 10/27/23
1.9400 -88.09%
on 01/04/23
-0.9990 (-81.22%)
since 12/08/22

Most Recent Stories

More News
Genprex (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”)...

GNPX : 0.2310 (+0.43%)
Genprex (NASDAQ: GNPX) to Present at BIO-Europe 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general...

GNPX : 0.2310 (+0.43%)
Genprex (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is hosting an upcoming virtual key opinion leader (“KOL”);...

GNPX : 0.2310 (+0.43%)
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 0.2310 (+0.43%)
Genprex (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference

Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical...

GNPX : 0.2310 (+0.43%)
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 0.2310 (+0.43%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 0.2310 (+0.43%)
RHHBY : 36.0000 (+1.18%)
JAZZ : 120.42 (+0.73%)
ALXO : 12.26 (+32.54%)
ACHL : 0.9400 (+5.32%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 0.2310 (+0.43%)
RHHBY : 36.0000 (+1.18%)
JAZZ : 120.42 (+0.73%)
ALXO : 12.26 (+32.54%)
ACHL : 0.9400 (+5.32%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

GNPX : 0.2310 (+0.43%)
RHHBY : 36.0000 (+1.18%)
JAZZ : 120.42 (+0.73%)
ALXO : 12.26 (+32.54%)
ACHL : 0.9400 (+5.32%)
Genprex (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company recently announced that the United States...

GNPX : 0.2310 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 0.2693
2nd Resistance Point 0.2597
1st Resistance Point 0.2453
Last Price 0.2310
1st Support Level 0.2213
2nd Support Level 0.2117
3rd Support Level 0.1973

See More

52-Week High 1.9400
Fibonacci 61.8% 1.2716
Fibonacci 50% 1.0652
Fibonacci 38.2% 0.8587
Last Price 0.2310
52-Week Low 0.1903

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar